This trial is conducted in Oceania. The aim of this trial is to assess whether dose adjustment is required for patients with renal impairment by investigating the pharmacokinetics of liraglutide in subjects with various degrees of renal impairment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Single dose of 0.75 mg, administered as a subcutaneous injection
Novo Nordisk Investigational Site
Christchurch, Australia
Area under the Curve (AUC)
AUC (0-t)
Cmax, maximum concentration
tmax, time to reach Cmax
t½, terminal half-life
CLR (renal clearance)
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.